Health Technology Report Names Viveve Regulatory Executive Among Top 25 Women Leaders in Medical Devices

News and research before you hear about it on CNBC and others. Claim your one week free trial for StreetInsider Premium here.

Viveve SVP Suzon Lommel Named to the List for the Second Consecutive Year for Her Efforts to Advance Innovative Technologies to Treat Stress Urinary Incontinence in Women

ENGLEWOOD, CO/ACCESSWIRE/January 13, 2022/ Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced that Suzon Lommel, the company’s Senior Vice President of Regulatory Affairs and Quality, has been named by The Healthcare Technology Report as one of the Top 25 Women Leaders in Medical Devices of 2022. Ms. Lommel was also named one of the Top 25 Women Leaders in Medical Devices in 2021.

“Over the past year, Viveve has been focused on developing our innovative technology for the treatment of stress urinary incontinence or SUI in women. The efforts of Suzon and all of our team members senior have demonstrated our commitment to leadership and innovation. Suzon has always worked to keep us ahead by anticipating and expertly addressing regulatory and quality issues, playing an important role in our progress. the Viveve organization congratulates Suzon for her outstanding contribution to the medical device industry and this well-deserved recognition,” said Scott Durbin, CEO of Viveve.

“In my role at Viveve, I have been fortunate to help advance our unique technology that has the potential to make a profoundly positive difference in the lives of millions of women affected by SUI. I am once again honored to be included with the other women recognized in the Healthcare Technology Report’s Top 25 Women Leaders in Medical Devices for 2022,” said Ms. Lommel. “This honor also highlights once again the outstanding progress of our entire team in its work to develop and bring our technology for the treatment of SUI to patients around the world as quickly as possible.”

The Health Technology Report annually recognizes top performers who have demonstrated depth of specialist knowledge and leadership to make a positive impact in the field of medical devices. Demonstrating qualities such as adaptability, ingenuity and patient orientation, winners play a pivotal role in advancing the competitiveness of their companies and technologies. They also serve as mentors and role models to promote and support leadership opportunities for women in the health technology sector.

About Viveve

Viveve Medical, Inc. is a medical technology company focused on women’s intimate health. Viveve is committed to providing new solutions to improve the general well-being and quality of life of women. The internationally patented Viveve® System incorporates cryogen-cooled monopolar radiofrequency technology to evenly deliver volumetric heating while gently cooling surface tissue to generate neocollagenesis in a single in-office session. In the United States, the Viveve® System is cleared by the Food and Drug Administration (FDA) for use in general surgical procedures for electrocoagulation and hemostasis. International regulatory approvals and clearances have been received for vaginal laxity and/or enhancement of sexual function indications in over 50 countries.

Viveve continues to advance its clinical development program in stress urinary incontinence (SUI). Viveve received FDA approval for its IDE application to conduct the multicenter, randomized, double-blind, simulation-controlled PURSUIT trial for improving SUI in women in July 2020 and approval from the FDA of its requested amendments to the IDE protocol in December 2020. The trial was reported in January 2021 and completion of subject enrollment was announced on December 14, 2021. The first results are expected in late 2022. If they are positive, the results of the PURSUIT trial may support a new SUI indication in the United States

For more information, visit the Viveve website at

Safe Harbor Statement

All statements in this press release that are not based on historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. forward-looking statements included in this press release about its current expectations, the information on which those expectations were based is subject to change. These forward-looking statements are based on a number of assumptions about future events and are subject to a number of risks, uncertainties and other factors, many of which are beyond our control, which could cause actual results differ materially from those statements. These risks, uncertainties and other factors include, but are not limited to, fluctuating global economic conditions, the impact of the novel coronavirus known as COVID-19 on our clinical development, regulatory review and approvals, and manufacturing. , placements and patient utilization. of our Viveve systems, the performance of management and our employees, our ability to obtain financing, our evaluation of strategic alternatives, our ability to obtain approval or clearance for sale of our medical device for all indications research, competition, general economic conditions and other factors which are detailed in our periodic and current reports available for review at Additionally, we operate in a highly competitive and rapidly changing environment where new and unforeseen risks may arise. Accordingly, investors should not rely on forward-looking statements as a prediction of actual results. We disclaim any intention and undertake no obligation to update or revise any forward-looking statements to reflect events or circumstances which occur subsequently or become known to us, except as required by law.

Viveve is a registered trademark of Viveve, Inc.

Investor Relations contacts:
Amato and Partners, LLC
Investor Relations Advisor
[email protected]

Media contact:
Bill Berry
Berry & Company Public Relations
(212) 253-8881
[email protected]

THE SOURCE: Viveve Medical, Inc.

See the source version on

Comments are closed.